Concepedia

Harry P. Erba

HP

Statistics

Publications

177

Citations

17.7K

H-Index

62

Active since

1980

Affiliations

Dana-Farber Cancer Institute(Current)

Fred Hutch Cancer Center

University of Alabama at Birmingham

The University of Texas MD Anderson Cancer Center

Cleveland Clinic

Harry P. Erba is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

1980–2025

177

Publications

177

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

, , +13

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

, , +15

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

R. Coleman Lindsley, Brenton G. Mar, Emanuele Mazzola et al. · Blood · 2014 · 977 citations · Full text

, , +14

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 952 citations · Full text

, , +10

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text

, , +16

1–5 of 177